SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotime-Nasdaq's best kept secret? -- Ignore unavailable to you. Want to Upgrade?

To: CMon who wrote (1268)3/5/1999 2:33:00 PM
From: Todd N. Weisrock  Respond to of 1432
 
Very good point, but you need to factor in commissions for those of us that have shares/rights, but not bajillions of them. Exercizing my rights costs me nothing, while selling my rights and buying shares costs me two trades. Of course, some brokerage firms will charge for the exercize of the rights... Everyone must do their own math...



To: CMon who wrote (1268)3/5/1999 2:44:00 PM
From: mesaone  Read Replies (1) | Respond to of 1432
 
Only a novice would comment about the rights offer without
understadning it.
Persons who fully subscribe can oversubscribe for any remaining
shares, plus 250,000 more.
This by itself raises par for btimr by 50% plus.
Those who have been buying the rights at a premium are the ones who
were short rights on February 17.
The volume on the rights has totalled over 3 million thus far.

inch.com


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News